Cargando…
Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer
BACKGROUND: National guidelines recommend trastuzumab for treatment of patients with metastatic HER2-positive gastric cancer (GC). There is currently no guideline indicating the number of biopsy specimens and the location from which they should be obtained to reliably determine the human epidermal g...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Japan
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824804/ https://www.ncbi.nlm.nih.gov/pubmed/25987463 http://dx.doi.org/10.1007/s10120-015-0502-3 |
_version_ | 1782426131975110656 |
---|---|
author | Tominaga, Naoyuki Gotoda, Takuji Hara, Megumi Hale, Matthew D. Tsuchiya, Takayoshi Matsubayashi, Jun Kono, Shin Kusano, Chika Itoi, Takao Fujimoto, Kazuma Moriyasu, Fuminori Grabsch, Heike I. |
author_facet | Tominaga, Naoyuki Gotoda, Takuji Hara, Megumi Hale, Matthew D. Tsuchiya, Takayoshi Matsubayashi, Jun Kono, Shin Kusano, Chika Itoi, Takao Fujimoto, Kazuma Moriyasu, Fuminori Grabsch, Heike I. |
author_sort | Tominaga, Naoyuki |
collection | PubMed |
description | BACKGROUND: National guidelines recommend trastuzumab for treatment of patients with metastatic HER2-positive gastric cancer (GC). There is currently no guideline indicating the number of biopsy specimens and the location from which they should be obtained to reliably determine the human epidermal growth factor receptor 2 (HER2) status in GC. The aim of this pilot study was (a) to quantify HER2-positive tumor cells in different tumor regions to assess the spatial heterogeneity of HER2 expression and (b) to establish the required number of biopsy specimens and the location from which they should be obtained within the tumor to achieve concordance between HER2 expression status in the biopsy specimens and the resection specimen. METHODS: HER2 expression was quantified in six different regions of 24 HER2-positive GC and in six virtual biopsy specimens from different luminal regions. Intratumoral regional heterogeneity and concordance between HER2 status in the biopsy specimens and the resection specimen were analyzed. RESULTS: HER2-positive cells were more frequent in the luminal tumor surface compared with deeper layers (p < 0.001). GCs with differentiated histological features were more commonly HER2 positive (p < 0.001). Assessment of HER2 expression status in five biopsy specimens was sufficient to achieve 100 % concordance between the biopsy specimens and the resection specimen. CONCLUSIONS: This is the first study to suggest preferential HER2 positivity at the luminal surface in GC and to establish a minimum number of biopsy specimens needed to obtain a biopsy HER2 result which is identical to that from the whole tumor. Our study suggests that HER2 testing in five tumor-containing endoscopic biopsy specimens from the proximal (oral) part of the tumor is advisable. The results from this pilot study require validation in a prospective study. |
format | Online Article Text |
id | pubmed-4824804 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Springer Japan |
record_format | MEDLINE/PubMed |
spelling | pubmed-48248042016-04-20 Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer Tominaga, Naoyuki Gotoda, Takuji Hara, Megumi Hale, Matthew D. Tsuchiya, Takayoshi Matsubayashi, Jun Kono, Shin Kusano, Chika Itoi, Takao Fujimoto, Kazuma Moriyasu, Fuminori Grabsch, Heike I. Gastric Cancer Original Article BACKGROUND: National guidelines recommend trastuzumab for treatment of patients with metastatic HER2-positive gastric cancer (GC). There is currently no guideline indicating the number of biopsy specimens and the location from which they should be obtained to reliably determine the human epidermal growth factor receptor 2 (HER2) status in GC. The aim of this pilot study was (a) to quantify HER2-positive tumor cells in different tumor regions to assess the spatial heterogeneity of HER2 expression and (b) to establish the required number of biopsy specimens and the location from which they should be obtained within the tumor to achieve concordance between HER2 expression status in the biopsy specimens and the resection specimen. METHODS: HER2 expression was quantified in six different regions of 24 HER2-positive GC and in six virtual biopsy specimens from different luminal regions. Intratumoral regional heterogeneity and concordance between HER2 status in the biopsy specimens and the resection specimen were analyzed. RESULTS: HER2-positive cells were more frequent in the luminal tumor surface compared with deeper layers (p < 0.001). GCs with differentiated histological features were more commonly HER2 positive (p < 0.001). Assessment of HER2 expression status in five biopsy specimens was sufficient to achieve 100 % concordance between the biopsy specimens and the resection specimen. CONCLUSIONS: This is the first study to suggest preferential HER2 positivity at the luminal surface in GC and to establish a minimum number of biopsy specimens needed to obtain a biopsy HER2 result which is identical to that from the whole tumor. Our study suggests that HER2 testing in five tumor-containing endoscopic biopsy specimens from the proximal (oral) part of the tumor is advisable. The results from this pilot study require validation in a prospective study. Springer Japan 2015-05-19 2016 /pmc/articles/PMC4824804/ /pubmed/25987463 http://dx.doi.org/10.1007/s10120-015-0502-3 Text en © The Author(s) 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Tominaga, Naoyuki Gotoda, Takuji Hara, Megumi Hale, Matthew D. Tsuchiya, Takayoshi Matsubayashi, Jun Kono, Shin Kusano, Chika Itoi, Takao Fujimoto, Kazuma Moriyasu, Fuminori Grabsch, Heike I. Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer |
title | Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer |
title_full | Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer |
title_fullStr | Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer |
title_full_unstemmed | Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer |
title_short | Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer |
title_sort | five biopsy specimens from the proximal part of the tumor reliably determine her2 protein expression status in gastric cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824804/ https://www.ncbi.nlm.nih.gov/pubmed/25987463 http://dx.doi.org/10.1007/s10120-015-0502-3 |
work_keys_str_mv | AT tominaganaoyuki fivebiopsyspecimensfromtheproximalpartofthetumorreliablydetermineher2proteinexpressionstatusingastriccancer AT gotodatakuji fivebiopsyspecimensfromtheproximalpartofthetumorreliablydetermineher2proteinexpressionstatusingastriccancer AT haramegumi fivebiopsyspecimensfromtheproximalpartofthetumorreliablydetermineher2proteinexpressionstatusingastriccancer AT halematthewd fivebiopsyspecimensfromtheproximalpartofthetumorreliablydetermineher2proteinexpressionstatusingastriccancer AT tsuchiyatakayoshi fivebiopsyspecimensfromtheproximalpartofthetumorreliablydetermineher2proteinexpressionstatusingastriccancer AT matsubayashijun fivebiopsyspecimensfromtheproximalpartofthetumorreliablydetermineher2proteinexpressionstatusingastriccancer AT konoshin fivebiopsyspecimensfromtheproximalpartofthetumorreliablydetermineher2proteinexpressionstatusingastriccancer AT kusanochika fivebiopsyspecimensfromtheproximalpartofthetumorreliablydetermineher2proteinexpressionstatusingastriccancer AT itoitakao fivebiopsyspecimensfromtheproximalpartofthetumorreliablydetermineher2proteinexpressionstatusingastriccancer AT fujimotokazuma fivebiopsyspecimensfromtheproximalpartofthetumorreliablydetermineher2proteinexpressionstatusingastriccancer AT moriyasufuminori fivebiopsyspecimensfromtheproximalpartofthetumorreliablydetermineher2proteinexpressionstatusingastriccancer AT grabschheikei fivebiopsyspecimensfromtheproximalpartofthetumorreliablydetermineher2proteinexpressionstatusingastriccancer |